In another study, ctDNA BRCA1 and BRCA2 reversal mutations were detected in 112 ovarian cancer patients treated with PARP inhibitors, with eight patients acquiring reversal mutations. This evidence concerns the gene BRCA2 and ovarian carcinoma.